Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Endocrinology

Understanding Your Diagnosis of LIPE-Related Familial Partial Lipodystrophy

At a Glance

LIPE-related FPLD6 is a rare genetic disorder that causes fat loss from the limbs and abnormal fat buildup elsewhere, often leading to insulin resistance, high triglycerides, and fatty liver. Diagnosis and care usually require an endocrinologist familiar with rare lipodystrophies.

Receiving a diagnosis of LIPE-related Familial Partial Lipodystrophy (FPLD6) means you have finally found a name for a set of symptoms that can be confusing and difficult to pin down. This condition is exceptionally rare; while general forms of lipodystrophy are uncommon, the LIPE-specific subtype is known through only a small number of families and clinical reports worldwide [1][2]. Because of this rarity, it is very common for local doctors to have never seen a case before, which often leads to a long and frustrating journey toward the right answer [3][4].

What is FPLD6?

In the simplest terms, Familial Partial Lipodystrophy (FPLD) is a genetic condition where the body has a reduced capacity for subcutaneous fat storage. Normally, fat is stored under the skin (subcutaneous fat) to provide energy and cushion the body. In FPLD6, a mutation in the LIPE gene disrupts this process.

The LIPE gene is responsible for making hormone-sensitive lipase, an enzyme that helps break down stored fats [1]. When this gene doesn’t work correctly, subcutaneous fat is lost from specific areas—most notably the legs and sometimes the arms—and instead undergoes ectopic fat accumulation in places it typically would not, such as the face, neck, and abdomen [1][5].

The Diagnostic Journey and Misdiagnosis

Because the symptoms overlap with more common conditions, it is frequently misdiagnosed. Age of onset and recognition vary, including possible childhood or adolescent recognition.

  • Metabolic Syndrome: Many patients are initially told they simply have common “metabolic syndrome” because they have high blood sugar, high triglycerides, and a “belly” [6]. However, unlike typical weight gain, the fat loss in your legs (lipoatrophy) is a hallmark of lipodystrophy that doesn’t happen in standard metabolic syndrome [7][8].
  • Multiple Symmetric Lipomatosis (MSL): Also known as Madelung’s disease, this condition causes large, non-cancerous fatty masses to grow around the neck, shoulders, and trunk. FPLD6 can look visually similar to MSL, but physical appearance alone cannot differentiate them; FPLD6 requires targeted clinical evaluation of the signature loss of fat in the legs and more severe metabolic problems [9][1].
  • Cushing Syndrome: Because fat can accumulate in the upper back (sometimes called a “buffalo hump”) and the face, doctors might test for high cortisol (Cushing syndrome) [10][11]. Appropriate clinical evaluation and targeted biochemical testing, rather than appearance alone, are needed to definitively rule it out [11].

Beyond the Surface: Metabolic and Physical Effects

FPLD6 is not just about how you look; it is a multisystem condition. When your body cannot store fat safely under the skin, that fat accumulates ectopically into your organs and blood [12]. This leads to:

  • Severe Insulin Resistance: Your body’s cells don’t respond well to insulin, often leading to difficult-to-manage diabetes [1][13].
  • Hypertriglyceridemia: Very high levels of fat in the blood, which can increase the risk of pancreatitis [1][7].
  • Fatty Liver: Fat builds up in the liver (steatosis), which can cause inflammation or scarring over time [1].
  • Reported Systemic Findings: Unique to the LIPE form of this disease, some patients have been reported to experience muscle weakness (myopathy) or small deposits in the back of the eye called drusen [1][14]. These are possible reported findings, not required established features.

Navigating the Emotional Impact

Living with a rare disease carries a heavy emotional burden. It is documented that patients in broader lipodystrophy populations often face a median diagnostic delay of over 10 years, seeing multiple doctors before getting an answer [3][15]. This uncertainty can lead to significant distress.

The changes in your physical appearance are not “cosmetic” issues—they are the external markers of your disease. Many patients report feelings of isolation, body-image distress, and frustration with a healthcare system that may not understand their condition [16][17]. Finding a specialist team—usually an endocrinologist with experience in rare lipid disorders—is the most critical step in managing both the physical and emotional aspects of FPLD6 [4][18]. Areas of the body that have lost fat will not “regrow” it through diet or exercise, so management focuses on protecting your heart, liver, and metabolic health [12][19].

Common questions in this guide

What is LIPE-related familial partial lipodystrophy, or FPLD6?
It is a very rare genetic disorder caused by a change in the LIPE gene, which affects how the body stores fat beneath the skin. Fat may be lost from the legs or arms while extra fat collects in areas such as the face, neck, or abdomen.
What health problems can FPLD6 cause?
FPLD6 can cause severe insulin resistance, high blood sugar or difficult-to-manage diabetes, and very high triglycerides. It may also lead to fatty liver and a higher risk of pancreatitis; muscle weakness and deposits called drusen in the eye have been reported in some people.
How is FPLD6 distinguished from metabolic syndrome, Madelung disease, or Cushing syndrome?
Doctors look at the pattern of fat loss and accumulation, metabolic findings, and the person’s history rather than appearance alone. Blood tests, hormone testing when needed, imaging, and LIPE genetic testing may help distinguish FPLD6 from these conditions.
What does a LIPE genetic result mean for my health?
A LIPE result can help confirm that changes in the gene are contributing to the pattern of fat loss and metabolic problems. It does not predict exactly whether you will develop diabetes, liver disease, or heart complications, so clinicians interpret it alongside examination findings, blood tests, and ongoing screening.
Which doctor should manage LIPE-related FPLD6?
An endocrinologist familiar with rare lipid disorders is often central to care. If local clinicians have not managed FPLD6, ask whether you can be referred to a specialist center with experience in lipodystrophy.
Can fat lost from my legs or arms grow back with diet or exercise?
Fat lost from affected areas will not regrow through diet or exercise. Care therefore focuses on protecting metabolic, liver, and cardiovascular health with an individualized plan from a qualified clinician.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What does my LIPE genetic result tell you about my specific risk for diabetes, liver disease, and heart complications?
  2. 2.Since my condition is so rare, do you have experience managing other forms of partial lipodystrophy, or can you refer me to a specialist center?
  3. 3.What targeted biochemical tests or imaging should we use to confidently distinguish my diagnosis from conditions like Cushing syndrome?
  4. 4.What screening should I have for non-metabolic symptoms like muscle weakness or changes in my vision?
  5. 5.Are there specific dietary or lifestyle modifications you recommend that differ from standard 'healthy living' advice?
  6. 6.Can you help me document my diagnosis so that insurers understand the difference between 'cosmetic' fat changes and my underlying metabolic disease?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells.

    Sollier C, Capel E, Aguilhon C, et al.

    European journal of endocrinology 2021; (184(1)):155-168.

    PMID: 33112291
  2. 2

    Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges.

    Chiquette E, Oral EA, Garg A, et al.

    Diabetes, metabolic syndrome and obesity : targets and therapy 2017; (10()):375-383 doi:10.2147/DMSO.S130810.

    PMID: 29066925
  3. 3

    Patients' perspective on the medical pathway from first symptoms to diagnosis in genetic lipodystrophy.

    Mosbah H, Vatier C, Andriss B, et al.

    European journal of endocrinology 2024; (190(1)):23-33 doi:10.1093/ejendo/lvad169.

    PMID: 38128113
  4. 4

    Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.

    Patni N, Chard C, Araújo-Vilar D, et al.

    Orphanet journal of rare diseases 2024; (19(1)):263 doi:10.1186/s13023-024-03245-3.

    PMID: 38992753
  5. 5

    Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy.

    Zolotov S, Xing C, Mahamid R, et al.

    American journal of medical genetics. Part A 2017; (173(1)):190-194 doi:10.1002/ajmg.a.37880.

    PMID: 27862896
  6. 6

    Familial Partial Lipodystrophy (FPLD): Recent Insights.

    Bagias C, Xiarchou A, Bargiota A, Tigas S

    Diabetes, metabolic syndrome and obesity : targets and therapy 2020; (13()):1531-1544 doi:10.2147/DMSO.S206053.

    PMID: 32440182
  7. 7

    Brazilian expert consensus on the diagnosis, classification, screening for complications and treatment of familial partial lipodystrophy.

    Valerio CM, Viola LF, Guidorizzi NR, et al.

    Diabetology & metabolic syndrome 2025; (17(1)):186 doi:10.1186/s13098-025-01733-5.

    PMID: 40452043
  8. 8

    Lipidomics analysis to assess metabolic complications in familial partial lipodystrophy type 2.

    Koue-Chon-Lim J, Beyene HB, Giles C, et al.

    Diabetes research and clinical practice 2026; (237()):113297 doi:10.1016/j.diabres.2026.113297.

    PMID: 42092697
  9. 9

    Lipomatoses.

    Dupuis H, Lemaitre M, Jannin A, et al.

    Annales d'endocrinologie 2024; (85(3)):231-247 doi:10.1016/j.ando.2024.05.003.

    PMID: 38871514
  10. 10

    An adolescent girl referred with Cushing syndrome--does she or does she not have the syndrome?

    Kao KT, Zacharin M

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(1)):109-12.

    PMID: 26677885
  11. 11

    Evaluation of the hypothalamic-pituitary-adrenal axis in a case series of familial partial lipodystrophy.

    Elias CP, Antunes DE, Coelho MS, et al.

    Diabetology & metabolic syndrome 2019; (11()):1 doi:10.1186/s13098-018-0396-4.

    PMID: 30622652
  12. 12

    The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

    Brown RJ, Araujo-Vilar D, Cheung PT, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.

    PMID: 27710244
  13. 13

    Lipodystrophy for the Diabetologist-What to Look For.

    Patni N, Garg A

    Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.

    PMID: 35821558
  14. 14

    Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene.

    Zhou Y, Zhang L, Ding Y, Zhai Y

    Frontiers in genetics 2024; (15()):1417613 doi:10.3389/fgene.2024.1417613.

    PMID: 39113684
  15. 15

    Diagnostic and referral pathways in patients with rare lipodystrophy and insulin-resistance syndromes: key milestones assessed from a national reference center.

    Donadille B, Janmaat S, Mosbah H, et al.

    Orphanet journal of rare diseases 2024; (19(1)):177 doi:10.1186/s13023-024-03173-2.

    PMID: 38678257
  16. 16

    "We're stuck with what we've got": The impact of lipodystrophy on body image.

    Adams C, Stears A, Savage D, Deaton C

    Journal of clinical nursing 2018; (27(9-10)):1958-1968 doi:10.1111/jocn.14342.

    PMID: 29516553
  17. 17

    Health-related Quality of Life, Social, and Psychological Well-Being of 109 Adult Patients With Genetic Lipodystrophy.

    Mosbah H, Vatier C, Andriss B, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(8)):e2532-e2543 doi:10.1210/clinem/dgae837.

    PMID: 39657019
  18. 18

    Experiences and Perspectives of Patients with Non-HIV-Associated Lipodystrophies and Their Caregivers: A Qualitative Study.

    Gomes A, Cook K, Wong A, et al.

    The patient 2021; (14(5)):673-685 doi:10.1007/s40271-021-00511-5.

    PMID: 33840079
  19. 19

    Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

    Mosbah H, Donadille B, Vatier C, et al.

    Orphanet journal of rare diseases 2022; (17(Suppl 1)):170 doi:10.1186/s13023-022-02308-7.

    PMID: 35440056

This page is for informational purposes only and does not constitute medical advice. An endocrinologist or rare-disease specialist should interpret your LIPE result and metabolic findings in the context of your care.

Get notified when new evidence is published on LIPE-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.